Overtreatment and excessive cost associated with primary versus secondary PARP inhibitor (PARPi) maintenance therapy for ovarian/peritoneal/fallopian tube cancer (EOC)

2021 ◽  
Vol 162 ◽  
pp. S225
Author(s):  
Peter Rose
Keyword(s):  
Maintenance Therapy ◽  
Fallopian Tube ◽  
Parp Inhibitor ◽  
Fallopian Tube Cancer

scholarly journals Severe folate deficiency anemia associated with the use of a PARP inhibitor (olaparib) in a patient with fallopian tube cancer

2018 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Binoy Yohannan ◽  
Kristi McIntyre ◽  
Mark Feldman
Keyword(s):  
Folic Acid ◽  
Fallopian Tube ◽  
Complete Blood Count ◽  
Parp Inhibitor ◽  
Folate Deficiency ◽  
Serum Folate ◽  
Deficiency Anemia ◽  
Folic Acid Deficiency ◽  
Fallopian Tube Cancer ◽  
Increased Risk

Treatment of cancer patients with olaparib (PARP inhibitor) is associated with an increased risk of anemia, which is seen in a majority of treated patients. However, symptomatic anemia requiring transfusion is rare. Olaparib-induced anemia can be secondary to bone marrow suppression, hemolysis or folate deficiency. We report a case of new onset severe folic acid deficiency anemia in a patient with breast and relapsed fallopian tube cancer being treated with olaparib. Complete blood count on admission showed a hemoglobin of 4.2 g/dl and serum folate was undetectable (< 1.6 ng/ml; reference range 7-31.4 ng/ml). This is the second report of olaparib-induced folate deficiency anemia. She received three units packed red cell transfusion and parenteral folic acid supplementation and improved symptomatically. This case highlights the importance of recognizing folate deficiency as a reversible cause of anemia with PARP inhibitor therapy.

scholarly journals Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Jing Ni ◽  
Xianzhong Cheng ◽  
Rui Zhou ◽  
Xia Xu ◽  
Wenwen Guo ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Parp Inhibitor ◽  
Advanced Ovarian Cancer ◽  
Burning Sensation ◽  
Short Term ◽  
Body Hair ◽  
Fallopian Tube Cancer ◽  
Term Efficacy

Abstract Purpose Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects and short-term efficacy in advanced ovarian cancer patients who administered Olaparib. Methods Patients with ovarian cancer, fallopian tube cancer and peritoneal cancer that treated with Olaparib in The Affiliated Cancer Hospital of Nanjing Medical University between September 2018 and June 2019 were recruited. The drug associated Adverse Events (AEs) were collected and short-term efficacy were analyzed by modified Response Evaluation Criteria in Solid Tumors (mRECIST) . Results Of all 28 enrolled patients, 92.9% were ovarian cancer, 7.1% were fallopian tube cancer, and 39.3% cases harbored germline BRCA-mutation. There were 6(21.4%) patients received Olaparib after multi-line chemotherapy, and 10 patients (35.7%) as second-line maintenance therapy and 2 patients (7.1%) as first-line maintenance therapy. There were still other 10 cases (35.7%) received Olaparib as exploratory therapy. Abdominal distention, decreased blood pressure, increased body hair, thirsty, burning sensation of stomach and leg swelling were newly reported AEs. Serious Adverse Events(SAEs) were usually managed by dose interruption or dose reduction, rather than discontinuation. 3 patients discontinued treatment, 8 patients received reduced dose of Olaparib, and 4 patients stopped therapy after the alleviation of AEs. Of all 28 enrolled cases, in monotherapy group, 1 of 6 patients achieved stable disease(SD) and also 2 patients achieved stable disease(SD) combined with anti-angiogenic drugs when disease progressed. 2 patients achieved complete remission(CR) and 3 patients were stable with exploratory therapy. Conclusions The AEs of Olaparib were all manageable. For the first time, we also identified several AEs such as abdominal distention, decreased blood pressure, increased body hair, thirsty, burning sensation of stomach and leg swelling during the follow-up which have not been reported. The short-term efficacy was observed in some exploratory cases that provided new potential indication to PARPi-related clinical trials.

scholarly journals Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

2021 ◽  
Author(s):  
Shannon N Westin ◽  
Marilyne Labrie ◽  
Jennifer Litton ◽  
Aurora Blucher ◽  
Yong Fang ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Fallopian Tube ◽  
Triple Negative ◽  
Mapk Pathway ◽  
Parp Inhibitor ◽  
Therapy Resistance ◽  
Akt Inhibitor ◽  
Fallopian Tube Cancer ◽  
Peritoneal Cancer ◽  
Phase 1B

Background: Combining poly (ADP-ribose) polymerase (PARP) with phosphatidylinositol-3-kinase (PI3K) pathway inhibitors is supported by strong preclinical rationale. We sought to assess safety and determine a recommended phase 2 dose (RP2D) for PARP inhibitor olaparib combined with the AKT inhibitor, capivasertib, and evaluate molecular markers of response and resistance. Methods: As part of a larger phase 1b trial, we performed a safety lead in of olaparib and capivasertib followed by expansion (n=24) in endometrial, triple negative breast, ovarian, fallopian tube, or peritoneal cancer. Olaparib 300mg orally twice daily and capivasertib orally twice daily on a four day on three day off schedule was evaluated. Two dose levels (DL) were planned: capivasertib 400mg (DL1); capivasertib 320mg (DL-1). Patients underwent biopsies at baseline and after 28 days. Findings: 38 patients were enrolled. 7 (18%) patients had known germline BRCA1/2 mutations. The first two patients on DL1 experienced dose limiting toxicities (DLTs) of diarrhea and vomiting in absence of maximum supportive care. No DLTs were observed on DL-1 (n=6), therefore, DL1 was re-explored (n=6) with no DLTs, confirming this as RP2D. Most common treatment-related grade 3 or 4 adverse events were anemia (23.7%) and leukopenia (10.5%). Of 32 subjects evaluable for response, 6 (19%) had partial response (PR) with a PR rate of 44.4% in endometrial cancer. Seven (22%) additional patients had stable disease greater than 4 months. Tumor analysis demonstrated strong correlation between response and immune activity, as well as alterations in cell cycle and DNA damage response genes. Therapy resistance was associated with receptor tyrosine kinase (RTK) and RAS-MAPK pathway activity, as well as metabolism and epigenetics. Interpretation: The combination of olaparib and capivasertib is well tolerated and demonstrates evidence of durable activity in women's cancers, with particularly promising response in endometrial cancer. Importantly, tumor samples acquired pre and on-therapy can help predict patient benefit.

scholarly journals 2085248 Fallopian Tube Cancer: Description Of Ultrasonographic Findings

2015 ◽  
Vol 41 (4) ◽  
pp. S10-S11
Author(s):  
Lourdes Hereter ◽  
Betlem Graupera ◽  
M. Angela Pascual ◽  
Francisco Tresserra ◽  
M. Angels Martinez ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Cancer

Fallopian Tube Cancer: Stepchild or Mother?

2007 ◽  
Vol 107 (3) ◽  
pp. 386-387 ◽  
Author(s):  
David M. Gershenson
Keyword(s):  
Fallopian Tube ◽  
Fallopian Tube Cancer
Sign in / Sign up

Export Citation Format

Share Document